These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8105799)

  • 1. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis.
    Kornhuber J; Weller M; Riederer P
    J Neural Transm Park Dis Dement Sect; 1993; 6(1):63-72. PubMed ID: 8105799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathophysiology and therapy of malignant neuroleptic syndrome].
    Weller M; Kornhuber J
    Nervenarzt; 1992 Nov; 63(11):645-55. PubMed ID: 1361662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome.
    Weller M; Kornhuber J
    Med Hypotheses; 1992 Aug; 38(4):329-33. PubMed ID: 1337136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome.
    Kornhuber J; Weller M
    Curr Opin Neurol; 1994 Aug; 7(4):353-7. PubMed ID: 7952245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.
    Kornhuber J; Weller M
    J Neural Transm Gen Sect; 1993; 92(1):57-65. PubMed ID: 8101093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine/glutamate interactions in Parkinson's disease.
    Lange KW; Kornhuber J; Riederer P
    Neurosci Biobehav Rev; 1997 Jul; 21(4):393-400. PubMed ID: 9195597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome.
    Weller M; Kornhuber J
    Arch Neurol; 1992 Sep; 49(9):900-1. PubMed ID: 1472253
    [No Abstract]   [Full Text] [Related]  

  • 8. Glutamatergic drugs in Parkinson's disease.
    Lange KW; Riederer P
    Life Sci; 1994; 55(25-26):2067-75. PubMed ID: 7997066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
    Greenamyre JT; O'Brien CF
    Arch Neurol; 1991 Sep; 48(9):977-81. PubMed ID: 1835370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Akinetic crisis in Parkinson disease].
    Bächli E; Albani C
    Schweiz Med Wochenschr; 1994 Jun; 124(23):1017-23. PubMed ID: 8023100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal.
    Thomas A; Onofrj M
    Mov Disord; 2005 Dec; 20(12):1671; author reply 1671-2. PubMed ID: 16149099
    [No Abstract]   [Full Text] [Related]  

  • 13. Amantadine in Parkinson's disease: pro and contra.
    Greulich W; Fenger E
    J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.
    Avorn J; Bohn RL; Mogun H; Gurwitz JH; Monane M; Everitt D; Walker A
    Am J Med; 1995 Jul; 99(1):48-54. PubMed ID: 7598142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant syndrome after neuroleptic discontinuation.
    Amore M; Zazzeri N
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1323-34. PubMed ID: 8868212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis and treatment of neuroleptic malignant syndrome.
    Ebadi M; Pfeiffer RF; Murrin LC
    Gen Pharmacol; 1990; 21(4):367-86. PubMed ID: 1974219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
    Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
    Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
    Fiore S; Persichino L; Anticoli S; De Pandis MF
    Acta Biomed; 2014 Dec; 85(3):281-4. PubMed ID: 25567468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.
    Gray NS
    Hum Psychopharmacol; 2004 Apr; 19(3):205-7. PubMed ID: 15079855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.